Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Part 1: Close Up Radio Welcomes Back Research Scientist Emmanuel J. Ajala

  • Broadcast in Medicine
Close Up Radio

Close Up Radio

×  

Follow This Show

If you liked this show, you should follow Close Up Radio.
h:362063
s:12293980
archived

Bronx, NY – Emmanuel Ajala is a biomedical researcher striving to solve and determined to come up with solutions to today’s deadliest infectious diseases from COVID-19, HIV, to breast cancer. Without biomedical researchers such as Emmanuel, preventing and curing diseases would be out of the question.

Emmanuel earned his B.Sc. in Chemistry from Fisk University, his M.Sc. in Chemistry, from Polytechnic University in Brooklyn.

He has also worked as a professor, surgical technician, and research scientist. Emmanuel is also a member of the American Association for the Advancement of Science, the American Chemical Society, and the New York Medical Association.

Emmanuel has been featured in Strathmore Who’s Who Worldwide for outstanding contributions and achievements involving diabetes, Ebola virus, HIV, and breast cancer. He’s also recognized in Global Who’s Who as a distinguished professional for outstanding achievements in Bio-medical research.

Emmanuel is a Lifetime Featured Member of Strathmore’s Who’s Who Worldwide Edition for his incredible contributions in the field of research.

With over 20 years’ experience, Emmanuel is responsible for the pathophysiological investigation of HIV infection and breast cancer and was instrumental in the deletion of the Ebola virus glycoprotein pathway critical to its glycosylation that triggered cell circle arrest. Currently, Ajala is actively involved in silencing the COVID-19 pathway through a set of glycoproteins derived from the immune system's dual mitochondrial and endosomal compartments.

He is on a mission to create a world where disease is no longer a concern because effective treatments will be widely available for all.

Emmanuel says we can work systemically and collectively to find effective drugs and get them into clinical trials.